Ivan Moiseev

GVHD prophylaxis in matched related stem cell transplantation: Why post-transplant cyclophosphamide can be recommended a study by the EBMT transplant complications working party

An ASTCT, CIBMTR, EBMT, and APBMT Consensus Statement Defining Response Criteria for Hematopoietic Cell Transplantation Associated Thrombotic Microangiopathy (TA-TMA) Directed Therapy

Improved GVHD-free relapse-free survival when rATG/ATLG is used in allo-HCT from matched sibling donors - an EBMT registry study by the Transplant Complications Working Party

PTCy versus ATG as graft-versus-host disease prophylaxis in mismatched unrelated stem cell transplantation

Endothelial Activation and Stress Index (EASIX) to predict mortality after allogeneic stem cell transplantation: a prospective study

ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?

Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study

Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party

Current incidence, severity, and management of veno-occlusive disease/sinusoidal obstruction syndrome in adult allogeneic HSCT recipients: an EBMT Transplant Complications Working Party study

Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study

ATG or no ATG? – survey of clinical practice in EBMT centers on behalf of the Transplant Complications Working Party of EBMT

PS1239 NIVOLUMAB FOR TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN'S LYMPHOMA (CHL): CLINICAL AND PATIENT‐REPORTED OUTCOMES